SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: recommendations from the French society for Immuno-Therapy of Cancer (FITC)
Since December 2019, the emergence of the severe acute respiratory syndrome (SARS)- coronavirus (CoV)-2, responsible for COVID-19 and its worldwide spread led to devastating medical, economic and social consequences. Recently approved anti-SARS-CoV-2 vaccines (SC2V) offer a new hope to end this crisis.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Marie-L éa Gauci, Clélia Coutzac, Roch Houot, Aurélien Marabelle, Céleste Lebbé Tags: Letter to the Editor Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Coronavirus | COVID-19 | France Health | Immunotherapy | Respiratory Medicine | SARS | Vaccines